2021
DOI: 10.1080/08820139.2021.1882486
|View full text |Cite
|
Sign up to set email alerts
|

Interleukin-10 Levels are Associated with Doxorubicin-Related Cardiotoxicity in Breast Cancer Patients in a One-Year Follow-Up Study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 41 publications
0
7
0
Order By: Relevance
“…They also mentioned that numerous earlier documents emphasized that DOXO causes the flow of inflammatory cytokines, including TNF-α, and they added the excessive increase of pro-inflammatory cytokines was proposed, by other researchers, as a main pathological reason behind DOXO-induced cardiac damage. Clinically, Alves et al ( 2022 ) also established that breast cancer patients who suffered from DOXO therapy-induced cardiotoxicity showed elevations in plasma IL-10 concentrations. In harmony with Saad et al ( 2019 ), disturbance in IL-10 levels is possible through the cytotoxic influence of the drug on leukocytes.…”
Section: Discussionmentioning
confidence: 99%
“…They also mentioned that numerous earlier documents emphasized that DOXO causes the flow of inflammatory cytokines, including TNF-α, and they added the excessive increase of pro-inflammatory cytokines was proposed, by other researchers, as a main pathological reason behind DOXO-induced cardiac damage. Clinically, Alves et al ( 2022 ) also established that breast cancer patients who suffered from DOXO therapy-induced cardiotoxicity showed elevations in plasma IL-10 concentrations. In harmony with Saad et al ( 2019 ), disturbance in IL-10 levels is possible through the cytotoxic influence of the drug on leukocytes.…”
Section: Discussionmentioning
confidence: 99%
“…The mechanism of DIC involves not only cardiac cell death, but also systemic immune response. Clinical studies in patients receiving DOXO showed that plasma levels of several cytokines and chemokines are altered in patients with cardiac dysfunction compared to normal subjects [ 7 , 47 ]. In animal studies, although pro-inflammatory gene expression in the myocardium does not increase and may even decrease after DOXO treatment [ 26 , 48 ], systemic elevation in pro-inflammatory cytokines including IL-1β, TNF-α, IL-6, and other chemokines have been reported in many studies [ 8 , 49 , 50 ].…”
Section: Discussionmentioning
confidence: 99%
“…Despite the significant results showing the potential of using NT-proBNP to identify patients with a higher risk of CTRCD, the authors concluded that the NT-proBNP is not a surrogate diagnostic tool for the detection of the early onset of CTRCD due to the fact that there was no gradual and/or sudden increase in the levels of NT-proBNP prior to the development of CTRCD. In the study by Alves et al, 2021 [ 125 ], elevated levels of NT-proBNP by 2.1-fold were detected in patients with cardiotoxicity (116.55 ± 107.66 pg/mL) at 7 days after the last infusion with doxorubicin compared to the baseline (54.51 ± 28.58 pg/mL; p < 0.05). The variability of results observed in the studies might be attributed to the different therapeutic regimens, the sample size, the time points assessed, the definition of cardiotoxicity used in each study, and/or the different assays used to detect NT-proBNP as supported by Bouwer et al, 2019 [ 124 ].…”
Section: Resultsmentioning
confidence: 99%